Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Canisar - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Canisar

Approved

STANDARD

Canisar

Sichuan Huiyu Pharmaceutical Company Limited.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: e32ff2408cd2b0ba
Company: Sichuan Huiyu Pharmaceutical Company Limited.
Type: Standard

Approval Details

Approval Id: e32ff2408cd2b0ba
Drug Approval Philippines Name: Canisar
Product Name: Canisar
Registration Number: DR-XY49117
Brand Name: Canisar
Generic Name: Irinotecan Hydrochloride
Dosage Form: Concentrate Solution for IV Infusion
Dosage Strength: 20 mg/mL
Manufacturer: Sichuan Huiyu Pharmaceutical Company Limited.
Importer: Oncolife Corporation
Distributor: Oncolife Corporation
Issuance Date: 25 March 2025
Expiry Date: 28 June 2029
Pharmacologic Category: Antineoplastic
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

e32ff2408cd2b0ba

Type

Standard

Back to Philippines FDA Approvals